Pharmaceuticals
Pharmaceutical manufacturers and their lobbying arm PhRMA. Active on drug pricing, FDA approval, Medicare Part D.
Tracked PAC receipts
$387,848
Tracked PAC giving
$2,642,276
Independent expenditures
$0
LDA lobbying spend
$208,783,843
How money flowed in this sector
IDonors put $388K into 10 sector PACs tracked here, led by ELI LILLY & COMPANY PAC, PHARMACEUTICAL RESEARCH & MANUFACTURERS OF AMERICA BETTER GOVERNMENT COMMITTEE, ELI LILLY AND COMPANY POLITICAL ACTION COMMITTEE.
IIThose PACs spent $3M supporting candidates and on independent expenditures, with the top tracked recipients being DSCC, NATIONAL REPUBLICAN CONGRESSIONAL COMMITTEE-LEGAL FUND, GUTHRIE FOR CONGRESS.
IIISector PACs and clients took documented positions on 10 policy outcomes, including Pharmacy Benefit Manager Reform Act; MARCH-IN Rights Proposal (NIH Framework); Insulin Price Caps - State-Level Legislation.
Network graph
Top sector PACs (by tracked giving)
Top donors to sector PACs
| # | Name | Tracked $ |
|---|---|---|
| 1 | JONSSON, PATRIKperson | $7K |
| 2 | DE FELIPPIS, MICHAEL R DR PH.D.person | $7K |
| 3 | HEINE, ROBERTperson | $7K |
| 4 | LIN, LINUS Sperson | $7K |
| 5 | OLEKSIW, JENNIFER L MRSperson | $7K |
| 6 | O'NEAIL, SHAWNperson | $7K |
| 7 | CROANING, JAMES P MRperson | $7K |
| 8 | YUFFA, ILYAperson | $6K |
| 9 | VAN SANT HOFFMAN, ELIZABETH ANNperson | $6K |
| 10 | GILROY, JAMES C IIIperson | $6K |
Top recipients of sector PAC spending
| # | Name | Tracked $ |
|---|---|---|
| 1 | DSCCpac | $200K |
| 2 | NATIONAL REPUBLICAN CONGRESSIONAL COMMITTEE-LEGAL FUNDpac | $60K |
| 3 | GUTHRIE FOR CONGRESSpac | $60K |
| 4 | SCOTT PETERS FOR CONGRESSpac | $56K |
| 5 | CONTINUING AMERICA'S STRENGTH AND SECURITY PACpac | $52K |
| 6 | GROW THE MAJORITYpac | $50K |
| 7 | THOMPACpac | $40K |
| 8 | IMPACTpac | $40K |
| 9 | KAINE FOR VIRGINIApac | $38K |
| 10 | CMTE. FOR HISPANIC CAUSES/BUILDING OUR LEADERSHIP DIVERSITY PAC (BOLD PAC)pac | $38K |
Policy outcomes the sector touched
| # | Outcome | Positions |
|---|---|---|
| 1 | Pharmacy Benefit Manager Reform Act legislation · introduced | 39 |
| 2 | MARCH-IN Rights Proposal (NIH Framework) regulation · proposed · proposed | 21 |
| 3 | Insulin Price Caps - State-Level Legislation legislation · enacted | 15 |
| 4 | Sugar Reform Act (S.832, 118th Congress) legislation · failed | 12 |
| 5 | Inflation Reduction Act - Energy Provisions (H.R.5376) legislation · enacted | 11 |
| 6 | Inflation Reduction Act - Drug Pricing Provisions (H.R.5376) legislation · enacted | 10 |
| 7 | GENIUS Act, Guiding and Establishing National Innovation for U.S. Stablecoins (S legislation · enacted | 8 |
| 8 | Prior Authorization Reform (Improving Seniors Timely Access to Care Act) legislation · introduced | 7 |
| 9 | Financial Innovation and Technology for the 21st Century Act (FIT21, H.R.4763) legislation · passed | 7 |
| 10 | CBDC Anti-Surveillance State Act, 119th Congress legislation · passed | 7 |
Methodology
Industry-level totals are computed by summing donations and lobbying filings where the donor, recipient, or client is tagged with the pharmaceuticals sector. Numbers reflect QPQ-tracked totals only and may understate the official FEC cycle totals where the inflow ingest is incomplete. Click any entity to see its full profile with the breakdown of tracked vs FEC cycle totals.